Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoldonrasib-based combination study in RAS G12D-mutant non-small cell lung cancer (Subprotocol C)
2025-521147-21-00Phase 2Authorised
- Sponsor
- Revolution Medicines
- Start
- Oct 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of zoldonrasib and daraxonrasib in non-small cell lung cancer (NSCLC), sponsored by Revolution Medicines. Primary endpoints: Incidence of dose-limiting toxicities and Safety and tolerability. Planned start Oct 2025; status: authorised.
02
Drugs
zoldonrasibdaraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521147-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521147-21-00.